VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MIRM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MIRMMirum Pharmaceuticals, Inc.
$92.49$5.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMIRMBalance Sheet

Mirum Pharmaceuticals, Inc. (MIRM) Balance Sheet

8Y historyFree accessUpdated daily

Total debt of $743.6M against cash of $243.2M and negative shareholders' equity of -$54.2M in 2026Q3 suggests a strained capital structure in which obligations exceed total assets, even though the current ratio remains at 2.07.

Income StatementBalance SheetCash FlowRatios

MIRM Balance Sheet

Annual statement

MIRM Balance Sheet

Mirum Pharmaceuticals, Inc. (MIRM) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets586.63M549.68M392.79M387.54M190.22M166.59M236.35M119.36M51.98M
Cash & Short-Term Investments373.69M383.33M280.31M286.33M151.72M156.54M231.82M116.66M51.96M
Cash Only243.19M296.68M222.5M286.33M28M31.34M142.09M11.97M51.96M
Short-Term Investments130.5M86.64M57.81M0123.72M125.2M89.73M104.69M0
Accounts Receivable156.35M123.33M78.29M67.97M23.99M4.37M000
Days Sales Outstanding75.9386.3584.82133.11113.6583.29---
Inventory25.49M24.89M22.4M22.31M5.57M1.51M000
Days Inventory Outstanding75.5890.31100.16173.13164.15290.2---
Other Current Assets31.11M18.14M11.78M10.94M8.95M4.17M0012K
Total Non-Current Assets439.98M293.13M277.97M259.08M162.68M128.06M4.51M27.35M0
Property, Plant & Equipment14.61M10.6M9.81M1.99M2.35M2.55M3.24M3.73M0
Fixed Asset Turnover49.19x49.17x34.33x93.66x32.86x7.51x---
Goodwill000000000
Intangible Assets275.65M260.92M249.82M252.93M58.95M18.74M000
Long-Term Investments292.26M8.11M12.53M004.98M023.29M0
Other Non-Current Assets22.96M13.5M5.81M4.17M101.38M101.79M1.27M324K0
Total Assets1.03B842.81M670.75M646.62M352.91M294.65M240.86M146.71M51.98M
Asset Turnover0.71x0.62x0.50x0.29x0.22x0.06x---
Asset Growth %129.46%25.65%3.73%83.23%19.77%22.33%64.17%182.27%-
Total Current Liabilities283.08M205.8M126.55M87.06M64.73M42.6M18.46M13.08M2.45M
Accounts Payable13.65M9.61M14.62M7.42M8.69M9.17M3.15M3.35M269K
Days Payables Outstanding78.8734.8965.3557.54256.331.76K1.85K3.78K-
Short-Term Debt000000000
Deferred Revenue (Current)000000000
Other Current Liabilities24.8M47.28M32.25M20.94M15.75M11.98M6.07M2.22M15K
Current Ratio2.07x2.67x3.10x4.45x2.94x3.91x12.80x9.13x21.22x
Quick Ratio1.98x2.55x2.93x4.19x2.85x3.88x12.80x9.13x21.22x
Cash Conversion Cycle72.64141.77119.62248.721.47-1.38K---
Total Non-Current Liabilities797.72M322.32M318.56M310.89M146.14M131.84M50.31M3.29M59.85M
Long-Term Debt731.25M309.8M308.08M306.42M00000
Capital Lease Obligations38.87M7.52M7.97M617K1.26M1.9M2.63M3.25M0
Deferred Tax Liabilities000000000
Other Non-Current Liabilities56.75M5.01M2.51M3.85M4.53M17K29K36K59.85M
Total Liabilities1.08B528.12M445.11M397.95M210.87M174.44M68.77M16.36M62.3M
Total Debt743.56M319.45M317.76M308.14M2.19M2.61M3.26M3.65M0
Net Debt500.37M22.77M95.26M21.82M-25.82M-28.73M-138.82M-8.32M-51.96M
Debt / Equity-13.72x1.02x1.41x1.24x0.02x0.02x0.02x0.03x-
Debt / EBITDA-5.19x151.54x-------
Net Debt / EBITDA-3.49x10.80x-------35.64x
Interest Coverage-73.82x-0.49x-5.07x-9.75x-7.89x-3.77x-307.25x--
Total Equity-54.19M314.69M225.64M248.67M142.04M120.21M172.09M130.35M-10.32M
Equity Growth %-179.21%39.47%-9.26%75.07%18.16%-30.15%32.03%1362.7%-
Book Value per Share-0.826.274.756.084.183.966.825.67-0.45
Total Shareholders' Equity-54.19M314.69M225.64M248.67M142.04M120.21M172.09M130.35M-10.32M
Common Stock7K5K5K5K4K3K3K2K6.99M
Retained Earnings-1.57B-667.54M-644.18M-556.24M-392.82M-257.16M-173.17M-69.9M-17.35M
Treasury Stock000000000
Accumulated OCI-2.06M351K-373K1.64M-217K-35K83K129K-66.84M
Minority Interest000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Deepening negative equity position

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Deteriorating Toward Negative Territory

According to reported SEC filings, MIRM's shareholders' equity fell from $314.7M in 2025Q4 to negative $54.2M in 2026Q3, as total liabilities climbed to $1.1B against total assets of roughly $1.0B.

The swing from positive equity to a deficit suggests accumulated losses and possibly large non-operating charges are eroding the capital base faster than new capital is replacing it. Retained earnings of roughly negative $1.6B point to a long record of losses rather than a single event. Investors should monitor whether the company can restore positive equity before liabilities further outpace assets.

Leverage Rising Against a Shrinking Equity Base

Based on EDBL-style reported figures, MIRM's total debt of $743.6M in 2026Q3 is more than 2.3 times its cash of $243.2M, and the company's debt-to-equity ratio is no longer meaningful with equity now negative.

Total debt has roughly doubled from about $319M in 2025Q4 to $743.6M, indicating a material step-up in borrowing rather than gradual accumulation. Because the company now carries more liabilities than assets, the balance sheet offers little cushion if refinancing terms tighten. The reported figures warrant further investigation into the maturity profile and covenant terms of this debt.

Current Ratio Holds While Cash Thins

As reported in financial statements, MIRM's current ratio of 2.07 in 2026Q3 remains above 2.0, but cash fell from $330.7M in 2026Q2 to $243.2M, a decline of about 26% in one quarter.

A current ratio above 2.0 suggests short-term assets still exceed short-term obligations, though the quarterly cash decline points to continued burn. The cash position relative to ongoing operating costs appears to be narrowing, which may indicate a shortening runway. Liquidity conclusions depend on the composition of current assets, which the supplied data does not fully break out.

Goodwill Anchors Asset Base Growth

Based on reported figures, goodwill of $275.6M in 2026Q3 is a meaningful share of total assets near $1.0B, and it rose from about $260.9M in 2025Q4 alongside an expanding asset base.

Goodwill comprising roughly a quarter of total assets raises impairment risk if the acquired revenue streams underperform, a concern given the company's persistent operating losses. Net PP&E of only about $14.6M indicates an asset-light model where value rests mainly on intangibles and cash. The rising goodwill balance warrants monitoring alongside any acquisition activity disclosed in future filings.

Headline Liquidity Masks Equity Shortfall

As reported in the financial statements, the current ratio of 2.07 may appear comfortable, yet negative shareholders' equity of -$54.2M means the company's obligations exceed its total assets.

A healthy-looking current ratio can coexist with a broader solvency problem when long-term liabilities are large, and here total liabilities exceed total assets. Stock-based compensation reported in the cash flow analysis may also be softening the cash picture by paying a portion of costs in equity, which dilutes existing holders. Headline liquidity metrics alone may therefore understate the balance sheet strain.

MIRM — Frequently Asked Questions

Quick answers to the most common questions about buying MIRM stock.

What are the total assets of Mirum Pharmaceuticals, Inc. (MIRM)?

As of 2025, Mirum Pharmaceuticals, Inc. (MIRM) had total assets of $842.8M including $549.7M in current assets.

How much debt does Mirum Pharmaceuticals, Inc. (MIRM) have?

Mirum Pharmaceuticals, Inc. (MIRM) carries total debt of $319.5M, offset by $383.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Mirum Pharmaceuticals, Inc.?

Mirum Pharmaceuticals, Inc. (MIRM) has total shareholders' equity (book value) of $314.7M ($6.27 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Mirum Pharmaceuticals, Inc.'s current ratio and liquidity?

Mirum Pharmaceuticals, Inc. (MIRM) reported a current ratio of 2.67x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.